Siloed use of Gen AI will limit its transformation potential

Dr Sidders brings two decades of deep data science experience, honed across multiple therapeutic areas at Pfizer and AstraZeneca. He will build on Biorelate's strong track record of leveraging advanced data science methods to extract critical knowledge from vast amounts of biomedical literature. These new data-derived insights are enabling drug developers to identify new targets with maximum market potential.

Using Galactic AI™, Biorelate synthesised insights from various biomedical studies into a coherent mechanism that underpins roflumilast's influence on airway inflammation and its prospective clinical benefits for non-CF bronchiectasis patients, by exploring the links between roflumilast and bronchiectasis.

Biorelate Founder and CEO is one of four to be presented with one of the Royal Academy of Engineering’s most prestigious individual awards